Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention

Mean platelet volume (MPV) is a well-established marker of platelet activation, and recent studies have shown that platelet activation is central to the processes in the pathophysiology of coronary artery disease (CAD). The study population consisted of 45 patients with stable CAD who underwent succ...

Full description

Saved in:
Bibliographic Details
Published in:Heart and vessels 2016-03, Vol.31 (3), p.269-274
Main Authors: Higaki, Tadanao, Kurisu, Satoshi, Watanabe, Noriaki, Ikenaga, Hiroki, Shimonaga, Takashi, Iwasaki, Toshitaka, Mitsuba, Naoya, Ishibashi, Ken, Dohi, Yoshihiro, Fukuda, Yukihiro, Kihara, Yasuki
Format: Article
Language:English
Subjects:
Aged
Aspirin - adverse effects
Aspirin - therapeutic use
Biomedical Engineering and Bioengineering
Blood platelets
Blood Platelets - drug effects
Cardiac Surgery
Cardiology
Cardiovascular disease
Clinical outcomes
Coronary Artery Disease - blood
Coronary Artery Disease - diagnosis
Coronary Artery Disease - therapy
Drug Monitoring - methods
Drug therapy
Drug Therapy, Combination
Drug-Eluting Stents
Female
Humans
Male
Mean Platelet Volume
Medicine
Medicine & Public Health
Original Article
Percutaneous Coronary Intervention - adverse effects
Percutaneous Coronary Intervention - instrumentation
Platelet Activation - drug effects
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Predictive Value of Tests
Reproducibility of Results
Retrospective Studies
Ticlopidine - adverse effects
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Time Factors
Treatment Outcome
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mean platelet volume (MPV) is a well-established marker of platelet activation, and recent studies have shown that platelet activation is central to the processes in the pathophysiology of coronary artery disease (CAD). The study population consisted of 45 patients with stable CAD who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents. We selected 45 age- and sex-matched control subjects without cardiovascular diseases who did not require antiplatelet therapy. Hematological test was performed 3 times within 1 month before DAPT (baseline), at 2 weeks after PCI (post PCI) and at 9 months after PCI (follow-up). Compared to control subjects, MPV was significantly larger in patients with CAD (10.0 ± 0.6 vs 10.7 ± 0.8 fl, p  
ISSN:0910-8327
1615-2573
DOI:10.1007/s00380-014-0599-z